Ann: NSB to investigate treatment for post-COVID Fibrosis, page-3

NeuroScientific Biopharmaceuticals to investigate treatment for post-COVID Fibrosis

• Neuroscientific Biopharmaceuticals (NSB) is partnering with The Institute of Respiratory Health and The University of Western Australia to test the effectiveness of EmtinB and other Metallothionein derived peptides (EmtinAc, EmtinAn, EmtinBn) as potential therapy for long term respiratory complications of Covid-19.
• With the number of COVID cases exceeding 50 million since December 2019 and rising rapidly, postCOVID fibrosis could become one of the largest future burdens on global healthcare.
• COVID patients who develop Acute Respiratory Distress Syndrome (ARDS) may survive the acute phase of the illness but can die as a result of progressive pulmonary fibrosis. Post-COVID fibrosis can cause lasting damage to the lungs even in young adult patients.
• Recently published data by an independent research organization demonstrated that Metallothionein, a natural form of EmtinB, can protect lungs from injury and fibrosis
• The preliminary data from this new program is expected to be available during the first half of 2021.